
Axsome Therapeutics' stock has increased following the release of Auvelity prescription data.
The increase comes after the FDA nodded to Auvelity for Alzheimer's agitation treatment.
Key Takeaways
Center
Not enough sources yet on this side — a blindspot summary will appear once outlets cover the story.
Not enough sources yet on this side — a blindspot summary will appear once outlets cover the story.
Get every side of the week's biggest story in your inbox.
Impact on Axsome Therapeutics' stock and the treatment of Alzheimer's agitation
No attributed perspective yet — we only show quotes grounded in analysis.
Evaluated across 1 reporting source (0% Left · 100% Center · 0% Right)
Historical editorial baseline for Seeking Alpha (US)
Multi-factor accuracy index for Seeking Alpha (US) and related desks based on verifiable sourcing and editorial standards.
Factuality: High 100%
Ownership: Seeking Alpha (US) (Corporate)
Public conversation related to this story
Loading comments…